There seems to be no confidence in the company as the stock price goes lower and lower. Do not expect anything positive from the meeting as the company is in early stage development. The vblock is a great product, but the stock is terrible. At some point we either go bankrupt or the company is sold with very little upside. This is my opinion. I have lost money here and many others have lost large blocks of money. Good luck to all. This reminds me of NIHD as that management should be in jail.
Issue 6 million shares on a new offering at 50 cents a share and do a 4 for 1 reverse split. Delisting is no option.
New York City-based Actinium is engaged in the development of therapies for diseases using its alpha particle immunotherapy platform and other related technologies. ATNM’s pipeline consists of Iomab-B and Actimab-A. The pipeline also includes products currently in pre-clinical stages. ATNM’s products are based on its Alpha Particle Immunotherapy (APIT) platform, a highly potent and selective form of targeted radiotherapy.
Iomab-B is ATNM’s most advanced product candidate. It has already been successfully used as a myeloconditioning/myeloablative agent in more than 250 patients with incurable blood cancers. ATNM is developing Iomab-B as an adioimmunotherapeutic that conditions relapsed and refractory Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). ATNM is about to begin a Phase III trial for its lead product candidate. The pivotal Phase III trial will enroll 150 AML patients over the age of 55.
Last year, ATNM made significant progress with its Iomab-B. However, this was not reflected in the performance of ATNM’s stock price last year. This was primarily due to the sharp correction in the biotech sector in the second half of 2015. Unfortunately for ATNM, the biotech sell-off has continued in 2016, pushing its shares close to 52-week low levels. For value investors though, this is an excellent opportunity.
ATNM has continued to achieve major milestones in 2016. In March, the U.S. FDA granted ATNM’s Iomab-B, an Orphan Drug designation. According to Sandesh Seth, Executive Chairman of Actinium, there has not been a new drug approved for relapsed and refractory AML patients over the age of 55 in decades and with Iomab-B being the only therapy of its kind, the company is pleased to achieve an important milestone in the form of an Orphan Drug designation.
That is not the only important milestone ATNM has achieved this year. In April, ATNM announced entered into an agreement with Zevacor Pharma Inc. for the clinical production and supply of Iomab-B for the Phase III SIERRA trial. According to the agreement, Zevacor Pharma will perform the Good Manufacturing Practices (GMP) manufacturing, testing, releasing and distribution of Iomab-B for Actinium's pivotal Phase 3 SIERRA trial. Zevacor Pharma is a leading developer, manufacturer, and distributor of radiopharmaceutical products and educational services used in nuclear medicine and molecular imaging in the U.S.
Actinium has also strengthened its clinical development team with the hiring of Director of Clinical Operations. The company appointed Jennifer Liberi to the position. Liberi will be in charge of managing Actinium's clinical trials, which will include, amongst other responsibilities, the training and leading of clinical trial sites, external service providers and internal staff, managing clinical trial budgets, supervising activities at clinical trial sites and preparing clinical aspects of regulatory submissions for Iomab-B, Actimab-A and future clinical programs. She joins Actinium from Noven where she served as Director, Clinical Operations. At Noven, Liberi planned and managed Phase 1 - 4 clinical trials and ensured that budgets and timelines associated with these trials were adhered to. Her responsibilities at Noven also included the preparation and review of protocols, consent forms, case report forms and other clinical trial documentation. Her inclusion provides a significant boost to Actinium’s clinical development at a crucial time for the company.
When one considers the progress ATNM has made and the fact that it has an advanced clinical pipeline, the current valuation is not justified. While the biotech sector sell-off has hurt valuations, companies with similar profile have much higher market capitalization. For example, Geron Corporation (NASDAQ: GERN), which is partnering with Janssen for its lead product candidate Imtelstat, currently has a market capitalization of more than $430 million. ATNM has a market capitalization of around $77 million. It must be noted though that ATNM is ahead if GERN in clinical stages. Xencor Inc. (NASDAQ: XNCR), another clinical stage company, currently has a market capitalization of more than $460 million.
Valuation of some of the development-stage companies in the CAR-T space are even higher. Kite Pharma Inc. (NASDAQ: KITE) for example has a valuation north of $2 billion. Juno Therapeutics Inc. (NASDAQ: JUNO) is valued at almost $4 billion. Even Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM), seen as an undervalued play in the CAR-T space, commands a valuation of more than $240 million.
The valuation anomaly between ATNM and other promising clinical stage biotechnology companies creates an excellent opportunity for value investors. One of the reasons for this valuation anomaly is the fact that ATNM has low institutional holding. However, this will change as the company is taking steps to increase awareness among institutional investors. Indeed, this year itself, ATNM has presented at multiple conferences, reaching out to the investor community. Once more institutions are on board, ATNM’s valuation should move closer to those of other promising clinical stage biotech companies.
They should have bought back alot shares at these low prices and then do a smaller reverse split, Now they are back where they started, a shell company. If they need capital, they will have to do another stock sale and increase the float even higher. Bad decisions by management is the only blame. Good luck to all shareholders. My rating here is a sell.
I agree. I think the company will be purchased before we see those high prices. I just bought more shares today. It cracks me up to see how these shorts come out on any pullback and have hard negative views to support their position with no regards for the fundamentals of the company. This stock is only a speculation.
Good luck to the shorts, you will need it!!!!
Silver is heavily shorted by most big brokerage houses, millions and millions of dollars. If they are forced to cover, you can expect a move to $ 25.00 very quickly. Watch out shorts. If a report comes out that demand is more than supply, you will see a massive short covering. Good luck!!
So the share price rises to 3 cents waiting for news of the merger, but it never comes, and the price crashes as insiders know the merger has failed and shareholders have no knowledge and get a press release after the fact. Way to go management. Thank you.
How long do you expect Dr. Royston to stay on the board. You could easily see a press release on his resignation. VPRO is a company with no assets or revenue and had a chance to merge with a company that has assets, revenue, and a pipeline of drugs, plus experienced employees, staff, and management. As a shareholder, I seen this merger making a lot of sense. Maybe it did not make sense for management. It is a lost opportunity. Are you willing to wait another three years for another letter of intent?
At least we got a press release. Management blew a great opportunity on this merger. Now we have to wait longer for another aquisition. It looks the reverse split will happen on the next aquisition. All this is very negative for the share price and I do not expect much appreciation in the near future. I only have a small position of 90K which I will hold. At earlier times, I had 750,000 shares expecting this merger. This is the second time this company could not complete a letter of intent to move forward. They could continue to produce letters of intent with no success and never really form a real company. This is a pattern which is not good for shareholders, only good for insiders. This is only my opinion. I was very positive and now I am neutral. Good luck.
SAN FRANCISCO, May 2, 2016 /PRNewswire/ -- Viropro, Inc. (VPRO) today announced that the non-binding Letter of Intent (the "LOI") the Company had signed in October 2015 to acquire NovaRx LLC ("NovaRx") has expired and that the acquisition contemplated in the LOI has not been consummated.
The Company remains committed to the strategy of acquiring private companies, raising capital in the public markets and structuring one or more spin-out transactions that will provide Viropro shareholders with a diversified portfolio of assets while retaining entrepreneurial incentives for the acquired companies. The Company is actively reviewing other possible acquisitions.
"We are disappointed that an agreement with NovaRx could not be reached under the terms of the LOI prior to its expiration," said Bruce Cohen, Interim Chairman of the Company's Board of Directors. "We continue to be very excited about the advances NovaRx has made in immuno-oncology and remain hopeful that we can come to an agreement."
Viropro also announced changes in the Company's roster of officers. In addition to Mr. Cohen's appointment as Interim Chair (replacing Kenneth Sorensen), previously announced in a Form 8-K filing, the Company appointed Michelle L.E. Peake as Secretary. Ms. Peake has served on the Board of Directors since 2012.
In addition, the Company's Board has appointed an Executive Committee, which currently consists of Mr. Cohen, Ms. Peake and Ivor Royston. The Executive Committee has been delegated all of the authority of the Board to the extent permitted by law, and is currently focusing on identifying alternative investments and raising capital to finance future acquisitions.
Separately, the Company has determined that it is not currently in the best interest of its shareholders to move forward with the reverse split and name change described in the preliminary information statement on Schedule 14C submitted by the Company to the SEC on March 10, 2016. "While we believe that a reverse split will be necessary in order for us to secure a NASDAQ listing, we intend to re-examine the timing and the ratio of the reverse split based on market factors and potential acquisitions," said Michelle Peake, Viropro's Secretary. "We also intend to defer the process of changing the Company's name and symbol."
Viropro Inc. In Watchlist
OTC Markets11:35 AM EDT
VIROPRO INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online 6 days ago
VIROPRO INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online 10 days ago
The Company is continuing its efforts to become compliant with SEC reporting rules by finalizing its audited financial statements for the period 2011-2014 and submitting required periodic reports. The Company has prepared its unaudited financial statements for these fiscal years; Viropro's independent registered public accounting firm is currently auditing the Company-prepared financial statements.
So many people have lost thousands of dollars here and people on this board are still pushing this stock. It is down 50 percent after the reverse split. It will go lower. It you want to take a chance, just do a small position. Good luck.
If anyone can give me reason to come back into this stock at these low prices, I am Listening. Good luck to all shareholders
Know what is going on. Another opportunity lost. The biosimiliar industry is going to boom in the future and VPRO will be left behind. Good luck to all shareholders.
I wish to thank management for screwing up this merger and destroying share price value without even issuing a press release and let share holders
My guess is the merger did not go through and Mr. Doll was not needed. If VPRO has to move forward on its own, it will take alot longer than expected. No other information was disclosed. Another opportunity has been missed. It may be possible other board members may be leaving. It is all speculation.
It looks like you are correct. The price indicates the merger is probably out. There has been no response from management since the stock was .03. It has collapsed back to where it has started. What a waste of time. I sold most of my shares about a month ago only holding a small position currently. Many have been here for years. Management blew another opportunity. I guess a press releaase will not be coming.